JP2024511412A5 - - Google Patents

Info

Publication number
JP2024511412A5
JP2024511412A5 JP2023558130A JP2023558130A JP2024511412A5 JP 2024511412 A5 JP2024511412 A5 JP 2024511412A5 JP 2023558130 A JP2023558130 A JP 2023558130A JP 2023558130 A JP2023558130 A JP 2023558130A JP 2024511412 A5 JP2024511412 A5 JP 2024511412A5
Authority
JP
Japan
Prior art keywords
approximately
glycoprotein
months
cov
fraction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023558130A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024511412A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/020974 external-priority patent/WO2022203963A1/en
Publication of JP2024511412A publication Critical patent/JP2024511412A/ja
Publication of JP2024511412A5 publication Critical patent/JP2024511412A5/ja
Pending legal-status Critical Current

Links

JP2023558130A 2021-03-22 2022-03-18 コロナウイルスワクチン製剤 Pending JP2024511412A (ja)

Applications Claiming Priority (17)

Application Number Priority Date Filing Date Title
US202163164487P 2021-03-22 2021-03-22
US63/164,487 2021-03-22
US202163176825P 2021-04-19 2021-04-19
US63/176,825 2021-04-19
US202163177059P 2021-04-20 2021-04-20
US63/177,059 2021-04-20
US202163195986P 2021-06-02 2021-06-02
US63/195,986 2021-06-02
US202163280395P 2021-11-17 2021-11-17
US63/280,395 2021-11-17
US202163290439P 2021-12-16 2021-12-16
US63/290,439 2021-12-16
US202163292196P 2021-12-21 2021-12-21
US63/292,196 2021-12-21
US202163293468P 2021-12-23 2021-12-23
US63/293,468 2021-12-23
PCT/US2022/020974 WO2022203963A1 (en) 2021-03-22 2022-03-18 Coronavirus vaccine formulations

Publications (2)

Publication Number Publication Date
JP2024511412A JP2024511412A (ja) 2024-03-13
JP2024511412A5 true JP2024511412A5 (https=) 2025-03-27

Family

ID=83396030

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023558130A Pending JP2024511412A (ja) 2021-03-22 2022-03-18 コロナウイルスワクチン製剤

Country Status (11)

Country Link
US (1) US20220332765A1 (https=)
EP (1) EP4313143A4 (https=)
JP (1) JP2024511412A (https=)
KR (1) KR20230160349A (https=)
AU (1) AU2022245141A1 (https=)
BR (1) BR112023019301A2 (https=)
CA (1) CA3213221A1 (https=)
IL (1) IL306088A (https=)
MX (1) MX2023011163A (https=)
TW (1) TW202304955A (https=)
WO (1) WO2022203963A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120227451A (zh) * 2018-03-19 2025-07-01 诺瓦瓦克斯股份有限公司 多价流感纳米颗粒疫苗
US10953089B1 (en) 2020-01-27 2021-03-23 Novavax, Inc. Coronavirus vaccine formulations
WO2023196634A2 (en) 2022-04-08 2023-10-12 Flagship Pioneering Innovations Vii, Llc Vaccines and related methods
WO2024151583A2 (en) 2023-01-09 2024-07-18 Flagship Pioneering Innovations Vii, Llc Vaccines and related methods
WO2024258829A1 (en) 2023-06-12 2024-12-19 Flagship Pioneering Innovations Vii, Llc Sars-cov-2 vaccine compositions and related methods
WO2025054236A2 (en) 2023-09-06 2025-03-13 Flagship Pioneering Innovations Vii, Llc Sars-cov-2 vaccine compositions and related methods
WO2025088585A1 (en) * 2023-10-25 2025-05-01 Novavax AB Saponin-based adjuvants and methods of characterizing same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2968510B1 (en) * 2013-03-14 2019-10-09 President and Fellows of Harvard College Nanoparticle-based compositions
US10953089B1 (en) * 2020-01-27 2021-03-23 Novavax, Inc. Coronavirus vaccine formulations
US20210228707A1 (en) * 2020-01-28 2021-07-29 Modernatx, Inc. Coronavirus rna vaccines
JP2023512519A (ja) * 2020-01-31 2023-03-27 ベス イスラエル ディーコネス メディカル センター インコーポレイテッド コロナウイルス感染症を予防および処置するための組成物および方法－ｓａｒｓ－ｃｏｖ－２ワクチン
US10906944B2 (en) * 2020-06-29 2021-02-02 The Scripps Research Institute Stabilized coronavirus spike (S) protein immunogens and related vaccines

Similar Documents

Publication Publication Date Title
JP2024511412A5 (https=)
GB2610070A (en) Coronavirus vaccine formulations
JP2026026092A5 (https=)
JP2023512648A5 (https=)
Chroboczek et al. Virus-like particles as vaccine.
EP0979284B2 (en) Reagents for vaccination which generate a cd8 t cell immune response
JP2023513720A5 (https=)
JP6595132B2 (ja) Ｈｉｖワクチン製剤
CN114404584B (zh) 一种新型冠状病毒mRNA疫苗及其制备方法和用途
JP2024516309A5 (https=)
JP6676661B2 (ja) ブタ生殖器呼吸器症候群及びブタサーコウイルス関連疾患に対するワクチン組成物
JP2006507800A (ja) 可撓性ワクチンアセンブリおよびワクチン送達プラットフォーム
Khan et al. Adenovirus-vectored SARS-CoV-2 vaccine expressing S1-N fusion protein
EP0951554A1 (fr) Proteine de fusion comportant tout ou partie de la proteine pp65 de cmv humain, utile notamment dans la preparation d'un vaccin
KR20250034195A (ko) B형 간염 면역화 레지멘 및 조성물
US20140199347A1 (en) Adjuvant compositions with 4-1bbl
US20240261392A1 (en) Compositions and methods to increase coronavirus immune response
US20220275346A1 (en) Hantavirus antigenic composition
RU2023126867A (ru) Вакцинные составы против коронавируса
US20220305112A1 (en) Novel methods and uses
US20050282263A1 (en) Flexible vaccine assembly and vaccine delivery platform
HK40088677A (en) Coronavirus vaccine formulations
US20250121053A1 (en) Vaccine compositions and their use
AU724621B2 (en) Amplification of response from expressed recombinant protein
Clark et al. Parainfluenza virus 5-based vaccine vectors expressing vaccinia virus (VACV) antigens provide long-term protection in mice from lethal intranasal VACV challenge